• Completed

NCT00573391: Phase 3: Study of Multiple Myeloma Patients Relapsing or Progressing After ASCT -TT2

Updated: Apr 25

NCT00573391: Phase 3: Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2


total therapy barlogie

Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2


This study is being done to find out if the combination of VelcadeTM with melphalan and dexamethasone (VMD) will be as effective, or even more effective as it is in combination with thalidomide and dexamethasone (VTD).


Sponsor:

University of Arkansas


Drug: Velcade, Thalidomide, and Dexamethasone

Drug: Velcade, Melphalan, and Dexamethasone

 

ClinicalTrials.gov Identifier: NCT00573391

Official Title: A Phase III Study for Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2 (TT2, UARK 98-026): Bortezomib, Thalidomide and Dexamethasone Versus Bortezomib, Melphalan, and Dexamethasone

First Posted : December 14, 2007


https://clinicaltrials.gov/ct2/show/NCT00573391

 

VDTPACE =

Velcade - Brtezomib

Thalidomide

Dexamethasone

Cisplatin

Adriamycin

Cyclophosphamide

Etoposide

 

Drug: Velcade

Drug: Thalidomide

Drug: Dexamethasone

Drug: Adriamycin

Drug: Cisplatin

Drug: Cyclophosphamide

Drug: Etoposide

 

Usmani SZ, Sexton R, Hoering A, Heuck CJ, Nair B, Waheed S, Al Sayed Y, Chauhan N, Ahmad N, Atrash S, Petty N, van Rhee F, Crowley J, Barlogie B.

Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.

Blood. 2012 Aug

https://pubmed.ncbi.nlm.nih.gov/22674807/



Posts Archive